Introduction
Cornelia de Lange syndrome (CdLS, MIM # 122470, MIM # 300590, MIM # 610759, MIM # 614701, and MIM # 300882) was initially described by Brachmann in 1916 and Cornelia de Lange in 1933 (1, 2) . CdLS is a multisystem malformation syndrome characterized primarily by 4 major clinical features including distinctive facial dysmorphism, developmental delay/intellectual disability (DD/ID), extremity abnormality, and hirsutism. However, a wide spectrum of abnormalities is observed among CdLS cases, which is partially attributed to underlying genetic heterogeneity. The causal genes identified to date consist exclusively of those encoding proteins seemingly related to the cohesin complex function. Nipped-B-like (NIPBL) and structural maintenance of chromosomes 1A (SMC1A) and 3 (SMC3) are the first 3 well-characterized causal genes for CdLS (3) (4) (5) (6) . Up to 60% of CdLS cases harbor mutations in NIPBL, which encodes a regulatory protein loading the cohesin complex onto the sister chromatids. Copy number variants (CNVs) in the NIPBL locus are found in approximately 5% of NIPBL point mutation-negative CdLS cases, while mosaic mutations in NIPBL are reported to account for an additional 23% (7) (8) (9) (10) . SMC1A and SMC3 are core structural components of the cohesin complex. Approximately 5% of CdLS cases are found to have missense mutations or small in-frame deletions in SMC1A and SMC3. RAD21 homolog (Schizosaccharomyces pombe) (RAD21) and histone deacetylase 8 (HDAC8) are the 2 most recently identified genes Cornelia de Lange syndrome (CdLS) is a genetically heterogeneous disorder that presents with extensive phenotypic variability, including facial dysmorphism, developmental delay/intellectual disability (DD/ID), abnormal extremities, and hirsutism. About 65% of patients harbor mutations in genes that encode subunits or regulators of the cohesin complex, including NIPBL, SMC1A, SMC3, RAD21, and HDAC8. Wiedemann-Steiner syndrome (WDSTS), which shares CdLS phenotypic features, is caused by mutations in lysine-specific methyltransferase 2A (KMT2A). Here, we performed whole-exome sequencing (WES) of 2 male siblings clinically diagnosed with WDSTS; this revealed a hemizygous, missense mutation in SMC1A that was predicted to be deleterious. Extensive clinical evaluation and WES of 32 Turkish patients clinically diagnosed with CdLS revealed the presence of a de novo heterozygous nonsense KMT2A mutation in 1 patient without characteristic WDSTS features. We also identified de novo heterozygous mutations in SMC3 or SMC1A that affected RNA splicing in 2 independent patients with combined CdLS and WDSTS features. Furthermore, in families from 2 separate world populations segregating an autosomal-recessive disorder with CdLS-like features, we identified homozygous mutations in TAF6, which encodes a core transcriptional regulatory pathway component. Together, our data, along with recent transcriptome studies, suggest that CdLS and related phenotypes may be "transcriptomopathies" rather than cohesinopathies.
in which mutations are associated with a CdLS-like phenotype: RAD21 encodes a key component of cohesin, providing a physical link between SMC1A and SMC3, while HDAC8 encodes a lysine deacetylase that regulates SMC3 (11, 12) .
Recently, it has become apparent that the cohesin complex not only functions in sister chromatid cohesion, but also plays a role in the regulation of transcription. Evidence suggests that NIPBL, SMC1A, SMC3, RAD21, and HDAC8, the 5 genes associated with cohesin and CdLS, are each involved in transcriptional regulation (11) (12) (13) (14) (15) (16) (17) . Variant alleles in genes encoding proteins important to cohesion function are also associated with other syndromes sharing phenotypic features with CdLS, such as Roberts-SC phocomelia syndrome (MIM # 268300, MIM # 269000) (18) and Warsaw breakage syndrome (MIM # 613398) (19) . Due to the extensive clinical heterogeneity and imperfect genotype-phenotype correlations, it is important to investigate the genetic heterogeneity underlying CdLS and CdLS-like phenotypes and to enrich our understanding of the phenotypic spectrum caused by the corresponding gene mutations, i.e., phenotypic expansion.
Sharing clinical features with CdLS, Wiedemann-Steiner syndrome (WDSTS, MIM # 605130) is another heterogeneous disease, first described by Wiedemann et al. in 1989 (20) . Also known as "hairy elbows syndrome," it is characterized by excessive hair growth around the distal third of the upper arm and the proximal third of the forearm and occasionally on other parts of the body (e.g., sacrum) along with short stature, distinctive facial features, and DD/ID. De novo deleterious mutations in lysine-specific methyltransferase 2A (KMT2A) were identified in patients with a clinical diagnosis of WDSTS (21) . However, these patients show a moderately different spectrum of clinical findings, indicating that different mutations in KMT2A, or allelic heterogeneity, contribute to a spectrum of phenotypes. To date, a wide spectrum of abnormalities in WDSTS is observed, among which hairy elbows is found as the most prominent shared clinical feature (21) (22) (23) .
Genetic studies of CdLS and the revelation of the various contributing cohesin proteins exemplify the use of a shared phenotypic definition to clinically derive a syndrome diagnosis, yet reveal a surprisingly complex genetic architecture that nonetheless has a unifying molecular role. To investigate a reciprocal approach interrogating the molecular basis of a disease phenotype, we initiated personal genome studies using whole-exome sequencing (WES), rather than interrogating variations at a specific locus, to determine whether patients with CdLS-like phenotypes, including WDSTS, harbor mutations in genes that are related to those known to underlie classical CdLS or perhaps reveal disease genes that may further broaden our understanding of the molecular perturbations leading to the CdLS phenotype. We report a previously unidentified, apparently recessive form of CdLS from 2 distinct world populations and provide evidence that CdLS could manifest as a result of a perturbed transcriptional profile and thus perhaps be better classified as a transcriptomopathy rather than a cohesinopathy. phic facial appearance, with micrognathia, long eyelashes, heavy eyebrows, synophrys, and large and prominent ears. Very striking excessive hair growth was also observed on the elbows, sacrum, and legs ( Figure 1 ). In silico investigation suggested that the 11-bp deletion, spanning the 23rd intron-exon junction, might affect splicing by removing the splicing acceptor on the 3′ end of the intron. We used subject-derived blood samples to test these in silico predictions and our alternative splicing hypothesis. Total RNA was obtained from 4 family members (patient, unaffected Prior to our study, only 1 de novo variant in SMC3 had been reported (6) . Interestingly, in our cohort, a previously unidentified de novo 11 base-pair deletion variant encompassing an intron-exon junction (Chr10: g.112360773 GTTACAGGAACT>G [hg19]) in SMC3 (NM_005445) was identified in a 17-year-old male patient (CdLS-1) (Tables 2 and 3 , and Figure 3A) . He presented with microcephaly, strabismus, hypermetropia, clinodactyly, restricted elbow movement, sandal gap of the feet, scoliosis, mild mixed-type hearing loss, hirsutism, DD/ID, and a dysmor- Note the eyebrows of the WDSTS-1 and WDSTS-2 are bushy, whereas the eyebrows of CdLS-1 and CdLS-3 have the typical arched appearance of CdLS with synophrys. WDSTS-1 and WDSTS-2 also have square and bulbous nasal tips. The second row of images demonstrates hirsutism of elbows in WDSTS-1, WDSTS-2, CdLS-1, and CdLS-2. Also of note is hirsutism of lower back, buttocks, legs, and face in the subjects. All individuals have modest brachydactyly of fingers and/or toes, and WDSTS-1, WDSTS-2, and CdLS-1 have fifth finger clinodactyly. WDSTS-1 and WDSTS-2 have pectus excavatum, and in CdLS-1, mild mid-thoracic scoliosis can be seen on the plain radiograph of the chest. jci. Figure 3C ).
Results

SMC1A variants in patients with
sister, and parents) and reverse-transcribed into cDNA, in which the alternative splicing product was validated through cDNA PCR followed by cloning and single-colony Sanger sequencing. Two different alternative splicing variants (SV1 and SV2) were The SV2 could only be detected using the cloning strategy but not in the Sanger sequencing of the cDNA PCR product, indicating that the amount of the SV2 in the peripheral blood of the patients was much less than the SV1 ( Figure 3 , A and C).
Remarkably, in an 8-month-old female patient (CdLS-2) with a phenotype of excessive hair growth on the elbows, lower back, buttocks, legs, and face, as observed in CdLS-1, we identified a de novo splicing-site mutation (ChrX: g.53410176 T>C [hg19]; c.2974-2A>G) in SMC1A ( Figure 3B ). The assay of cDNA PCR followed by cloning and single-colony Sanger sequencing was also performed for the cDNA derived from the patient's peripheral blood. A splicing variant utilizing an alternative splicing acceptor inside exon 21 was detected, which resulted in an in-frame deletion of 3 aa (p.D992_Q994del) ( Figure 3D ). In both cases, CdLS-1 and CdLS-2, the splicing-site mutations of SMC3 and SMC1A each resulted in alternative splicing variants without leading to frameshift outcomes. Concordantly, the splicing machinery in these 2 cases found alternative splicing sites in the downstream exons, which resulted in in-frame deletions that might be less deleterious. It is possible that highly deleterious mutation (i.e., frameshift or nonsense) in SMC3 and SMC1A, which may be incompatible with early embryo development, may be strongly selected against. This observation is also consistent with the fact that the reported mutations in SMC1A and SMC3 are either missense mutations or small in-frame deletions. In addition to the prominent hairy elbows phenotype, the patient CdLS-2 also presented with short stature, prenatal growth retardation, failure to thrive, microcephaly, short neck, bilateral sensorineural hearing loss, hirsutism, mild extremity problems, DD/ID, and dysmorphic facial appearance, including micrognathia, long philtrum, long eyelashes, thick eyebrows, synophrys, thin upper lip, and high arched palate (Table  1) . She also had retinitis pigmentosa, which could potentially be explained by a homozygous mutation (Chr1: 94473807 C>T [hg19]; c.G5882A, p.G1961E) in ABCA4 (NM_000350), the most frequently observed disease-associated mutation (~11%) of European ancestry ( Figure 3B and ref. 29) .
KMT2A and TAF6 variants in patients with CdLS-like phenotypes.
The extensive overlapping clinical findings between CdLS and WDSTS together with the finding of mutation in SMC1A in WDSTS patients prompted us to postulate that CdLS and WDSTS also share underlying biological mechanisms and rare variants in genes encoding proteins involved in similar genetic pathways underpinning these 2 syndromes. We analyzed the patients in the Turkish CdLS cohort in whom molecular diagnosis was inconclusive from known CdLS-associated genes (total number = 18/32 with no molecular diagnosis) in order to identify potential disease genes. Remarkably, in 1 female patient (CdLS-3) we identified a heterozygous nonsense mutation (Chr11: g.118344107 C>T [hg19]; c.C2233T, p.Arg745Ter) in KMT2A (NM_005933), the causal gene for WDSTS (21) . Segregation analysis in the family confirmed that this mutation was not present in the parents or the healthy elder brother, indicating it to be a de novo mutation in the patient (Figure 4 ). This mutation was not observed in ESP, TGP, and ARIC and was predicted to be damaging by SIFT (30), PolyPhen-2 (31), LRT (32) , and MutationTaster (refs. 32, 33, and Table 2 ).
CdlS-3 was a 21-month-old Turkish female with a healthy 7-year-old brother and was born to nonconsanguineous healthy parents. She was referred to the clinic due to developmental and growth delay. Physical examination was notable for short stature, microcephaly, clinodactyly, hirsutism, DD/ID, and facial dysmorphism, with long philtrum, thin and arched eyebrows, synophrys, long eyelashes, thin upper lip, and high arched palate ( Figure 1 and Table 1 ). Although a variant in the gene associated with WDSTS was identified, she did not appear to have a hairy elbows phenotype, the most prominent and distinctive clinical feature among patients clinically diagnosed with WDSTS; however, she had a facial appearance more consistent with CdLS. p.Ile71Thr) was identified in a cohort of multiplex consanguineous Saudi families with syndromic ID. The family consists of first-cousin, once-removed healthy parents with 5 children and 1 miscarriage ( Figure 5C ). Three of their children (2 sons, DG932/DG936, and 1 daughter, DG933, as shown in Figure 5C ) were referred for evaluation because of ID and dysmorphic features. The 3 siblings had hisrutism, broad great toes and Y-shaped 2-3 toe syndactyly, and mild facial dysmorphism in the form of thick bushy eyebrows with synophrys, low frontal hairline, a prominent nose, and long columella. These clinical features are reminiscent of a CdLSlike phenotype. Homozygosity mapping revealed several shared blocks of AOH ( Figure 5D ). Filtering of the exome variants by the coordinates of these homozygous intervals revealed a single variant in TAF6 that segregated with the phenotype within the family: the 3 affected individuals were found to be homozygous for the mutation. Consistent with recessive Mendelian inheritance, the unaffected siblings were WT reference, while the parents were both heterozygous carriers ( Figure 5D ). The variant was absent in a collection of 516 Saudi exomes from King Faisal Specialist Hospital and Research Center and was listed in ESP with an allele frequency of 1:13,000, a very low frequency compatible with a rare variant causing disease in the homozygous state. PolyPhen-2 and SIFT scores also revealed likely pathogenicity (Table 2) . Autosomal-recessive inheritance of CdLS or CdLS-like phenotypes is a previously unreported trait. To investigate the properties of the 2 disease-associated cosegregating mutations identified in the patients, we performed functional assays in Drosophila S2 cell lines. TAF6 is well conserved between human and Drosophila, and it stabilizes the core promoter-recognition TFIID complex (34) . In addition, the N-terminal region of TAF6 (TAF6N) is sufficient for TFIID stability in S2 cells (34) . Given that both mutations locate in the histone fold of the N-terminal region, we tested the interaction ability of the hTAF6N mutant proteins with 4 components in the TFIID complex, including dTAF1, dTAF4, dTAF9, and dTBP. We transiently knocked down the endogenous Drosophila TAF6 (dTaf6) in S2 cells using dsRNAs targeting the C-terminal region of dTAF6 (dTaf6C) I71T largely reduced the binding ability with all the components. Nevertheless, both hTAF6N mutants lost their interaction with dTBP. Therefore, these 2 mutations disrupted the interactions between TAF6 and other TFIID components, which may lead to the instability of this complex ( Figure 5E ). To further investigate the potential functional consequences of these 2 TAF6 mutations, we examined their effect on cell survival/growth in Saccharomyces cerevisiae. We transformed the expressing plasmids of ytaf6 WT , ytaf6mt1 (corresponds to hTAF6N R46C ), and ytaf6mt2 (corresponds to hTAF6N I71T ) into the yeast taf6 temperature-sensitive strain. Yeast spot assays were performed at both permissive and restrictive temperatures. There was a slight but not obvious reduction in the growth patterns in mutant transformants (Supplemental Figure 1 ; supplemental material available online with this article; doi:10.1172/JCI77435DS1). The result was not very surprising, Among the 32 Turkish patients with a clinical diagnosis of CdLS, 7 patients (21.875%) were born to consanguineous parents, indicating a potential contribution of recessive alleles to CdLS phenotypes. We investigated the personal genomes of these patients for recessive rare and potential pathogenic variants. In 1 patient (CdLS-4), we identified a deleterious homozygous variant (Chr7: g.99711697 G>A [hg19]; c.C136T, p.Arg46Cys) in TAF6 (TBP-associated factor, where TBP indicates TATA-box binding protein, 80 KD, NM_005641), which was not observed in any control databases and was predicted to be damaging by SIFT, PolyPhen-2, LRT, and MutationTaster (Table 2) .
This subject was a 4-year, 6-month-old male born to consanguineous parents and characterized with typical CdLS clinical features including short stature, microcephaly, narrow shoulders, single transverse palmar crease on the right hand, undescended testicle on the left, hirsutism, DD/ID, and dysmorphic facial appearance, including arched eyebrows with synophrys, long curly eyelashes, a widow's peak, long philtrum, prominent nose, microstomia, and thin upper lip ( Figure 5A ). Four other children were reported in the family, including an unaffected brother, an unaffected 17-year-old sister with seizures and ID, a sister who died at 9 months of age, and a brother who died at 5 months of age. According to the parents, both the deceased brother and sister were small for gestational age and had a phenotype similar to our subject. Segregation analysis showed that the parents and the unaffected sister were heterozygous carriers for the variant identified, while the unaffected younger brother was homozygous WT ( Figure 5B ). The variant also occurred in 1 of the regions of absence of heterozygosity (AOH), which likely resulted from identity by descent from the consanguineous marriage ( Figure 5B ).
To provide further evidence for a potential recessive CdLS or CdLS-like phenotype, we studied exomes of patients in recessive kindreds from a Saudi Arabian clinical population. Independently, a variant in TAF6 (Chr7: g. 99711522 A>G [hg19] ; c.T212C, The phenotypic/genotypic similarity between WDSTS and CdLS is further consolidated by the identification of a de novo SMC1A splicing-site mutation in the patient CdLS-2 with combined CdLS and WDSTS clinical features. It is interesting that we observed different disease expressivity between the 2 brothers harboring the identical mutation in SMC1A. The elder brother presented more severe clinical WDSTS features than the younger brother. Specifically, the elder appeared to have more prominent findings of hairy elbows and sacrum (Figure 1) . The difference may potentially be due to underlying genetic modifiers that can alter the phenotype caused by the SMC1A mutation. We capitalized on the availability of personal genome sequences to examine for a potential modifier gene by comparing the rare variants uniquely observed in each brother. Interestingly, a homozygous missense mutation (Chr20: g.58455447 A>G [hg19]; c.T2852C, p.Ile951Thr) was found in synaptonemal complex protein 2 (SYCP2, NM_014258) in the more severely affected elder brother, while it was heterozygous in the mildly affected younger brother and both unaffected parents ( Figure 2 , A and B, and Supplemental Table 1 ). The variant is at a low frequency (0.23% in ESP, 0.05% in TGP, and 0.5% in ARIC), highly conserved, and predicted to be deleterious. The homozygous variant also mapped within an AOH region in the elder brother ( Figure  2C ), indicating a potential distant relationship between the parents. Our in silico investigation of SYCP2's functions and interactions revealed that SYCP2 encoded a key component of the synaptonemal complex (SC) involved in chromosomal synapsis during meiosis. This component was also shown to act as a close interacting partner with the cohesin complex by strongly interacting with SMC1A, SMC3, and RAD21 gene products according to evidence from STRING v9.1 (ref. 36 and Figure 2D ). We speculate that defects in SYCP2 might contribute to the additional and more severe phenotypic findings in the elder brother by epistasis.
This finding remarkably underscores that mutations in potential modifier genes may alter the expressivity of the disease phenotypes caused by the same driver mutation. Mutations in a modifier may either aggravate or mitigate the symptoms attributable to the driver mutation. In the case of the brothers with WDSTS, we speculate that homozygous mutation in SYCP2 may lead to the more severe phenotype observed in WDSTS-1. The known interactions of SYCP2 with the protein products of CdLS-associating genes are consistent with this epistasis hypothesis ( Figure 2D ). Moreover, these findings also support the hypothesis that mutational load in an individual may disrupt the biological balance and lead to the occurrence or aggravation of a disease phenotype.
KMT2A potentially expands the genes associated with CdLS. KMT2A encodes a histone methyltransferase catalyzing histone H3 lysine 4 methylation (H3K4me), which plays an important role in chromatin-mediated transcriptional regulation during embryogenesis, cell fate determination, and cell-cycle progression as well as stem cell function. To date, all mutations reported in the WDSTS patients are exclusively de novo nonsense/frameshift alleles leading to immediate/subsequent gains of stop codons in the downstream sequences (ref. 21 and Figure 6B ). The de novo nonsense mutation identified in CdLS-3 was found in a patient diagnosed with CdLS rather than WDSTS. In this patient, we observed overlapping features of CdLS and WDSTS as well as several unique features of WDSTS. However, since the patients with the homozygous variants, although having clinically apparent developmental defects, still survived through development and beyond. It indicates that these mutations may be compatible with life. Thus, this yeast growth assay may not be an optimal and conclusive approach to studying the downstream effects of these 2 perhaps more subtle mutations.
Discussion
SMC1A and SMC3 contribute to phenotypes resembling WDSTS.
SMC1A is the causal gene for the X-linked CdLS cases presenting with milder phenotypes (5, 6). The identification of an SMC1A mutation in a family segregating WDSTS could reflect a potential role for cohesin genes/proteins in the molecular etiology of WDSTS. As one of the key components in the cohesin complex, SMC1A forms a tripartite ring structure with SMC3, RAD21, and stromal antigens (STAGs) to hold the sister chromatids together by trapping them inside the ring (35) . SMC1A contains 2 NTPase head domains in the NH 2 and COOH termini, respectively, and 1 hinge domain in the middle linked to the 2 terminal head domains by the coiled-coil domains. To date, all the causative mutations reported in CdLS are missense mutations or small in-frame deletions in the NTPase and coiled-coil domains, and the missense mutation found in WDSTS-1 and WDSTS-2 is in the N-terminal NTPase domain ( Figure 6A ). WDSTS-1 and WDSTS-2 share clinical phenotypes similar to those of other patients with SMC1A mutations within the same domain but without the hairy elbows feature (Table 1) .
Sharing a structure similar to that of SMC1A, SMC3 forms a V-shaped SMC1A/SMC3 heterodimer in the tripartite ring structure via the interaction between the hinge domains (6). The structural and functional similarities between the gene products of SMC1A and SMC3 imply that genetic variation in the 2 genes may result in similar phenotypes. The striking overlapping WDSTS clinical findings between patient CdLS-1, with an SMC3 mutation, and patients WDSTS-1/ WDSTS-2, with an identical familial X-linked hemizygous SMC1A mutation, not only substantiate this implication, but also strongly correlate the WDSTS phenotypes with CdLS, as both can be caused by defects in cohesin genes. shared and relatively unique phenotypic features would suggest a shared pathophysiology among these disorders. Our identification of potential causative mutations in KMT2A and TAF6 emphasizes that genes involved in epigenetic modification, chromatin remodeling, and transcriptional regulation pathways may be associated with CdLS. X-linked α-thalassemia/mental retardation syndrome (ATRX, MIM # 301040), KBG syndrome (KBGS, MIM # 148050), Kabuki syndrome (KS, MIM # 147920, MIM # 300867), RSTS, FLHS, Coffin-Siris syndrome (CSS, MIM # 135900), and WDSTS all share phenotypic features overlapping with those observed in CdLS (Table 4) . Interestingly, the genes associated with these syndromes are all involved in epigenetic modification, chromatin remodeling, and transcriptional regulation pathways: ATRX-associated gene ATRX encodes a helicase modifying chromatin structure and regulating the transcription of downstream genes (41, 42) ; ANKRD11, mutations of which can result in KBGS, encodes a negative regulator of ligand-dependent transcriptional activation (43) ; KS-associated genes KMT2D and KDM6A encode interacting histone H3K4 methyltransferase and H3K27 demethylase, respectively (44, 45) ; CREBBP (associated with RSTS) and SRCAP (associated with FLHS) encode interactalthough she had hirsutism, she did not present with hairy elbows and sacrum. CdLS-specific phenotypes were also observed in the patient ( Table 1 ). The blended clinical findings of CdLS with WDSTS in this patient suggest that KMT2A, the known gene for WDSTS, may potentially contribute to the phenotypic expansion of CdLS.
Phenotypic features and mutations in KMT2A and TAF6 connect CdLS to transcription machinery defects. It has been noted that there may be phenotypic overlap between WDSTS and Floating-Harbor syndrome (FLHS, MIM # 136140). A report of individuals in a family with hairy elbows but with facial features more consistent with FLHS has been published (37) . Additionally, there is a recent case of a boy with a CdLS phenotype and a mutation in EP300 (38) , a gene mutated in about 3% of individuals with Rubinstein-Taybi syndrome (RSTS, MIM # 180849), which is associated with milder abnormalities of the digits. Finally, the phenotypic overlap between FLHS and RSTS has long been noted (39, 40) , which is not surprising, given that the gene that causes FLHS, SRCAP, is a coactivator of CREBBP, the gene mutated in the majority of individuals with RSTS. When these disorders are thought of together, shared phenotypic features begin to emerge, including long eyelashes, hirsutism, abnormal eyebrows, limb and digit abnormalities, and growth deficiency (Table 4 ). These associated with the RSC complex (mutations of its components in human may result in CSS) in nucleosome positioning, chromatin remodeling, and transcriptional regulation (51) . These functional molecular studies correlate with our clinical and genomic analysis in patients with CdLS and CdLS-like features, where we identified variants in proteins involved in transcriptional regulation. Biochemical data obtained from studies in Drosophila reveal interactions between RAD21, one of the major structural components of cohesin complex, and the trithorax-group proteins; these link the cohesin components and chromatin-remodeling proteins into the same pathway of transcriptional regulation (refs. 52, 53, and Figure 7 ). In addition, genome-wide studies suggest the association between cohesin and RNA polymerase II (Pol II), which is also the interacting partner of the TFIID complex (ref. 17 and Figure 7) . TFIID is a megadalton-sized multiprotein complex necessary for RNA Pol II-initiated transcription, which reads epigenetic markers or interacts with transcriptional activators. It consists of TBP and TAFs (54) , which include TAF6 as a major component. TAF6 is conserved from yeast to human. In Drosophila, TAF6 together with other TAFs (TAF4, TAF5, TAF9, and TAF12) form the functional core of TFIID, and RNAi knockdown targeting TAF6 shows its role in stabilizing the TFIID complex (55) . It is not immediately apparent why perturbation of a component of a ubiquitously expressed general transcription factor complex may result in a tissue-specific phenotype, such as CdLS. However, we do note that knockdown of TAF6 in Drosophila resulted in a phenotype restricted to the wing area, suggesting a morphogenetic function of TAF6 ing partners, both of which are involved in transcriptional coactivation (46, 47) ; mutations in genes encoding subunits of SWI/ SNF complex, which encompasses the protein product of SRCAP (48) , have also been identified in patients with CSS (49). More interestingly, in a recently published study of a cohort of patients with CdLS or CdLS-like phenotypes, de novo mutations in the KBGS-associated gene ANKRD11 were identified, demonstrating the phenotypic overlap between KBGS and CdLS (50) . From the comparisons among different genes, gene functions, and clinical features (Table 4) , a picture of perturbed transcriptional regulation-associated phenotypes, perhaps a "transcriptomopathy," begins to emerge. In aggregate, the evidence above suggest that different syndromes that share phenotypic overlaps may harbor highly penetrant Mendelizing genetic variants involved in similar molecular pathways.
Defects in components of cohesin complex, especially those in NIPBL, are to date the major causes of CdLS. However, in addition to its crucial role in chromosome segregation, cohesin is also strongly suggested as regulating transcription. NIPBL is reported to be a regulator of gene expression in either cohesin-dependent or -independent manners (15) . Moreover, by using FISH in cells from patients with CdLS harboring NIPBL mutations, Nolen et al. have shown that defects in NIPBL result in the regional decompaction of higher-order chromatin architecture occurring at gene-rich genomic intervals, suggesting NIPBL's association with the transcription machinery (13) . A recent study by Lopez-Serra et al. shows in yeast that Scc2 (yeast orthologue of human NIPBL) is intimately other cohesinopathies, but also with disorders such as RSTS and FLHS that are caused by mutations in genes related to transcription. We therefore assert the importance of the contribution of transcription machinery to the phenotypes and molecular etiologies of CdLS-like phenotypes. Given a selected patient population with a high rate of consanguinity, potential recessive genes may also be identified. We propose that TAF6 may act as a potential responsible gene for autosomal-recessive CdLS.
Methods
Human subjects. This study was approved by the Institutional Review Board at BCM and King Faisal Specialist Hospital and Research Center. Informed consent was obtained from all subjects prior to enrollment in the project. All subjects were evaluated by one or more clinical geneticists. Genomic DNA was extracted from whole blood using the Gentra Puregene Blood Extraction Kit per the manufacturer's protocol (QIAGEN). All the genomic studies, including aCGH and WES, were performed on DNA samples extracted from whole blood.
CdLS array CGH.
We initially performed our in-house CdLS high-density aCGH targeting of cohesin/condensin genes (7) in all patients with clinical diagnoses of CdLS and WDSTS prior to submission to the WES pipeline to exclude potential pathogenic CNVs. To summarize the array design, an Agilent 8X60K format was used to include 46 genes (Supplemental Table 2 ) that belong to cohesin/ condensin complex families and their upstream/downstream 50 kb genomic regions. The array was designed using the Agilent eArray website (https://earray.chem.agilent.com/earray/), with average probe density of about 5 probes per 1 kb. All array procedures including DNA fragmentation and labeling, array hybridization, washing, and scanning were performed according to the manufacturer's instructions and previously described protocols (57) with minor modifications. Sex-matched female control (NA15510) DNA and male control (NA10851) DNA were obtained from Coriell cell repositories (Coriell Institute for Medical Research; http://ccr.coriell.org). Data processing and analyses were done using Agilent Feature Extraction Software (version 11.5, Agilent Technologies) and Agilent Genomic Workbench (edition 7.0, Agilent Technologies).
CMA. Agilent customized whole-genome array (BCM CMA version 9.1.1) was performed on patients WDSTS-1 and WDSTS-2 (24, 58, 59 ). Since KMT2A is not targeted on the CdLS aCGH as a candidate gene, the CMA could investigate any potential pathogenic CNVs in the KMT2A locus and the entire genome. The array design and experimental procedures were described previously (24, 57) .
WES and data analysis. Thirty-two Turkish patients with CdLS and 2 patients with WDSTS (WDSTS-1 and WDSTS-2) underwent WES at the BCM Human Genome Sequencing Center (BCM-HGSC) through the Baylor-Hopkins Center for Mendelian Genomics research initiative.
Genomic DNA samples were constructed into Illumina pairedend precapture libraries according to the manufacturer's protocol (Illumina Multiplexing Sample Preparation Guide 1005361 D) with modifications as described in the BCM-HGSC protocol (https://www. hgsc.bcm.edu/content/protocols-sequencing-library-construction). Libraries were prepared using Beckman robotic workstations (Biomek NXp and FXp models). Briefly, from 0.5 to 1 μg of DNA was sheared into fragments of approximately 300-400 base pairs with the Covaris E210 system following end-repair, A-tailing, and ligation of the Illumi- (56) . The defects in TAF6 may result in perturbed transcriptions initiation by RNA Pol II. From this perspective of transcriptional regulation, it is intriguing that we identified recessive TAF6 mutations in 2 separate world populations enriched for recessive disease-associated variants due to a high rate of consanguinity.
As the cohesin may participate in the same pathway as the genes involved in transcriptional regulation, the identification of deleterious mutations in TAF6 strongly supports the hypothesis that defects of genes involved in the transcription machinery, such as complexes with function of chromatin structure remodeling and transcriptional regulation, may result in a spectrum of disorders resembling CdLS. The aggregate evidence above suggest that these genes may contribute to phenotypes with characteristic core clinical features (Table 4 ) that may reflect a global disturbance in transcriptional regulation or a class of disorders that could constitute a "transcriptomopathy."
In summary, we identified a deleterious mutation in SMC1A, a causal gene of CdLS, in 2 related Turkish patients with a clinical diagnosis of WDSTS. Reciprocally, from a cohort of 32 Turkish patients with clinical diagnoses of CdLS, we also identified a deleterious mutation in KMT2A, the causal gene of WDSTS, in 1 CdLS patient. Moreover, in the CdLS cohort, we identified 1 deleterious mutation in SMC3 and 1 in SMC1A in 2 independent patients with clinical features resembling those seen in both CdLS and WDSTS. Since CdLS is a heterogeneous disorder with limited molecular etiologies, additional genetic variations await to be uncovered. In this study, we emphasize the clinical overlap of CdLS not only with alignment/map (BAM) file underwent quality recalibration using GATK (http://www.broadinstitute.org/gatk/) and, where necessary, the merging of separate sequence-event BAMs into a single samplelevel BAM. BAM sorting, duplicate read marking, and realignment to improve insertion/deletion (indel) discovery all occur at this step. WES for the Saudi family was performed using the TruSeq Exome Enrichment kit (Illumina) following the manufacturer's protocol. Samples were prepared for the Illumina sequencing library, with enrichment for the desired targeting using the Illumina Exome Enrichment protocol. The captured libraries were sequenced using Illumina HiSeq 2000 Sequencer, and reads were mapped against UCSC hg19 by BWA. Single-nt polymorphisms and indels were detected by SAMTOOLs. The resulting 77814 variants were filtered according to homozygosity, predicted pathogenicity and location within the autozygome (61) .
The findings of WES studies were deposited into the NCBI's ClinVar archive (SCV000195835, SCV000195836, SCV000195837, SCV000195838, SCV000195839, SCV000195840, SCV000195841, SCV000195842, SCV000195843, SCV000195844, SCV000195845, SCV000195846, SCV000195847, SCV000195848, SCV000195849, SCV000195850, SCV000195851, SCV000195852).
PCR validation and segregation analyses. The variants of interest were confirmed by Sanger sequencing following PCR amplification, and segregation analyses were performed on all available members of the families. Same pairs of primers are utilized for both PCR amplification and Sanger sequencing. Primer sets and their corresponding families are listed in Supplemental Table 3 . PCR reactions are performed following the protocols for HotStarTaq DNA Polymerase (QIAGEN).
B-allele frequency calculation and homozygosity mapping. To detect regions with AOH, we used B-allele frequency data obtained from both cSNP arrays and WES. B-allele frequency from WES was determined by computing the variant/total reads ratio for each SNP present in VCF file. The regions with AOH were identified using in-house scripts in R language (www.r-project.org) and the circular binary segmentation algorithm (62) . Alternatively, genotyping data from the Axiom SNP Chip platform (Affymetrix) was utilized to calculate AOH using AutoSNPa (63) .
Splicing-site mutation analysis. Blood samples for splicing-site mutation analysis were collected using the PAXgene blood RNA tube (PreAnalytiX). Total RNA was extracted using PAXgene blood RNA kit (PreAnalytiX) by following the manufacturer's protocol (http://www. qiagen.com/resources/resourcedetail?id=dc649975-b6ba-43e7-a3e9-e9986c612d2e&lang=en). cDNA was obtained using SuperScript III First-Strand Synthesis System for RT-PCR kit (Invitrogen) by following the manufacturer's protocol (http://tools.lifetechnologies. com/content/sfs/manuals/superscriptIIIfirststrand_pps.pdf). Primers used for PCR amplification of the normal alleles and alternatively spliced alleles are listed in Supplemental Table 4 . Sanger sequencings were performed to verify the alternative splicing site.
Cloning was performed to resolve the heterozygous alleles from PCR amplification. PCR amplification product was ligated into pCR4-TOPO vector using the TOPO TA Cloning Kit (Invitrogen) and transformed into One Shot TOP10 competent cells (Invitrogen). Cells after transformation were plated onto LB-agar plates supplemented with 50 μg/ml of kanamycin. Single colonies were picked from the plates after 37°C overnight culture and inoculated into LB-liquid medium with kanamycin for 37°C overnight culture in suspension. The plasmids na multiplexing PE adaptors. Precapture ligation-mediated PCR (LM-PCR) was performed for 6 to 9 cycles of amplification using either the 2X SOLiD Library High Fidelity Amplification Mix (a custom product manufactured by Invitrogen), the Phusion High-Fidelity PCR Master Mix (NEB, M0531L) or KAPA HiFi DNA Polymerase (Kapa Biosystems Inc., KM2602). Purification was performed with Agencourt AMPure XP beads (Beckman, A63882) after enzymatic reactions, and, following the final purification, quantification and size distribution of the precapture LM-PCR product were determined using the LabChip GX electrophoresis system (PerkinElmer).
In preparation for cocapture, the uniquely barcoded precapture libraries were pooled in equimolar amounts into 4-or 6-plexes using 1 μg per pool (for libraries prepared with the Invitrogen and KAPA enzymes) or 2 μg per pool (for libraries prepared with the Phusion enzyme). Each 4-plex library pool was then hybridized in solution to the HGSC-designed core capture reagent (52 Mb, NimbleGen) according to the manufacturer's protocol (NimbleGen SeqCap EZ Exome Library SR User's Guide) with minor revisions, while 6-plex library pools used the custom VCRome 2.1 capture reagent (42 Mb, NimbleGen). Human COT1 DNA and full-length blocking oligonucleotides were added into the hybridization to block repetitive genomic sequences and adaptor sequences. Postcapture LM-PCR amplification was performed for 12 to 14 cycles of amplification with the enzyme used in precapture library preparation. After the final AMPure XP bead purification, quantity and size of the capture library were analyzed using the Agilent Bioanalyzer 2100 DNA Chip 7500. The efficiency of the capture was evaluated by performing a qPCR-based quality assay on the 4 standard NimbleGen internal controls. Successful enrichment of the capture libraries was estimated to range from a 6 to 9 of ΔCt value over the nonenriched samples.
Library templates were prepared for sequencing using Illumina's cBot Cluster Generation System with TruSeq PE Cluster Generation Kits (PE-401-3001) according to the manufacturer's protocol. Briefly, these libraries were denatured and diluted in hybridization buffer in order to achieve a load density of approximately 800 K clusters/mm. Each library pool was loaded in a single lane of a HiSeq flow cell, and each lane was spiked with 2% phiX control library for run quality control. The sample libraries then underwent bridge amplification to form clonal clusters, followed by hybridization with the sequencing primer. Sequencing runs were performed in paired-end mode using the Illumina HiSeq 2000 platform. Using the TruSeq SBS Kits (FC-401-3001), sequencing-by-synthesis reactions were extended for 101 cycles from each end, with an additional 7 cycles for the index read. With the sequencing run yielding an average of approximately 9.6 Gb per sample, samples achieved an average of 92% of the targeted exome bases covered to a depth of 20× or greater.
Initial sequence analysis was performed using the HGSC Mercury analysis pipeline (https://www.hgsc.bcm.edu/software/mercury) (60) . In summary, the bcl files produced on-instrument were first transferred into the HGSC analysis infrastructure by the HiSeq Realtime Analysis Module. Mercury then ran the vendor's primary analysis software (CASAVA) to de-multiplex pooled samples and generate sequence reads and base-call confidence values (qualities), followed by the mapping of reads to the GRCh37 Human reference genome (Genome Reference Consortium; http://www.ncbi.nlm.nih.gov/ projects/genome/assembly/grc/human/) using the Burrows-Wheeler aligner (BWA; http://bio-bwa.sourceforge.net/). The resulting binary jci. (CEN HIS3 taf6-19) ]) according to standard protocols. Nutrition restrictions on uracil, histidine, and leucine were used to maintain the transformed plasmid and the original ytaf6 temperature-sensitive construct in YSB 552. For dilution spot assays, yeast cells grown to logarithmic phase at room temperature were initially diluted to 7 OD/ml. Subsequent 10-fold dilutions were made and spotted using the Replica plater. Plates were incubated at room temperature and at 37°C. In this experiment, pRS316 empty vector was used as a negative control.
Study approval. This study was approved by the Institutional Review Board at BCM (H-29697) and the King Faisal Specialist Hospital and Research Center (RAC# 2080006). Informed consent was obtained from all subjects prior to enrollment in the project. Written informed consent to use the photographs of patients appearing in the figures was also obtained.
were extracted from each cell culture using QIAprep Spin Miniprep Kit (QIAGEN), and M12-forward and M12-reverse primers (Invitrogen) were used for Sanger sequencing.
Constructs for TAF6 mutation used in functional assays. For constructs used in co-IP experiments, WT or mutated N-terminal regions of hTAF6 (hTAF6N WT , hTAF6N
R46C
, and hTAF6N
I71T
) were cloned into pUASTattB vectors with an N-terminal FLAG tag. For making dTaf6 dsRNA to knock down endogenous Drosophila Taf6, the C-terminal region of dTaf6 was cloned into the pUASTattB vector and used as a template for in vitro transcription using the MEGAscript RNAi Kit (Life Technologies). For constructs used in yeast experiments, 1 kb upstream and downstream sequences of ytaf6 were cloned into the pRS316 vector as regulatory regions. Full-length transcripts of WT ytaf6 and mutant ytaf6 with the corresponding mutations in humans (ytaf6mt1 and ytaf6mt2) were also cloned into pRS316 vectors. Cloning and DNA purification were performed based on standard protocols. Enzymes were from NEB, and DNA purification kits were from Invitrogen and QIAGEN. All constructs were Sanger sequenced before performing experiments.
Cell culture, co-IP, and Western blot. The Drosophila S2 cell line was cultured in Schneider's media (Lonza) with 10% FBS (Thermo Scientific) and antibiotics mix (Gibco; Life Technologies) at room temperature. The transfection was performed using Effectene (QIAGEN) according to the manufacturer's instructions. Proteins were expressed using the Actin-GAL4/UAS system. In co-IP experiments, cells were treated with dsRNA against the C-terminal region of dTAF6 and then transfected with pUASTattB-hTAF6N constructs. Cells were harvested 48 hours after transfection and lysed on ice in lysis buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 5% glycerol, 0.5% Triton X-100, and EDTA-free cocktail complete protease inhibitor; Roche). Lysate supernatant was incubated with 1% BSA preblocked EZ red α-HA beads (Sigma-Aldrich) overnight. Beads were washed with lysis buffer and boiled in 2× Laemmli buffer. SDS-PAGE, transfer, and Western blot were performed according to standard protocols. Primary antibodies were used at the following dilutions: rabbit α-FLAG antibody, 1:2000 (Abcam, ab1162); mouse α-dTAF4 antibody, 1:1000 (34); mouse α-dTAF9 antibody, 1:100 (34); mouse α-dTAF1 antibody, 1:100 (34); and mouse α-dTBP antibody, 1:100 (34). Goat HRP-conjugated secondary antibodies were used at 1:3000 dilution (Jackson ImmunoResearch, 115-035-166, 111-035-144). Membranes were developed using Western Lightning Plus-ECL (PerkinElmer) followed by x-ray film (Genemate) detection. jci.org Volume 125 Number 2 February 2015
